Yazarlar : Li J, Huang B, Li Y, Zheng D et al

Yayın : Leuk Lymphoma

Yayın Yılı : 2014

Pubmed Linki : http://www.docguide.com/hepatitis-b-virus-reactivation-multiple-myeloma-patients-receiving-bortezomib-containing-regimens-fo?tsid=5

Konu : Enfeksiyon

Literatür İçeriği :  Abstract In order to investigate HBV reactivation and survival in MM patients receiving bortezomib-containing regimens, we analyzed 139 MM patients receiving bortezomib-containing regimens in our hospital. 27/139 patients were HBsAg+ with 9 of them having DNA levels>500IU/ml including 4>1000 IU/ml. All but 5 HBsAg+ patients were treated with lamivudine or entecavir before chemotherapy until at least 6 months after chemotherapy or ASCT. HBV reactivation occurred in 6 HBsAg+ patients and 2 HBsAg- patients, including 6 who received an ASCT. OS and PFS of HBsAg- patients were significantly longer than HBsAg+ patients (both P values<0.01). In view of these results, we confirmed that incidence of HBV reactivation was notable in MM patients receiving bortezomib-containing regimens, especially those underwent ASCT. HBsAg+ MM patients had poorer prognosis than HBsAg- patients. Prophylactic treatment should be prescribed to all HBsAg+ MM patients for a minimal duration of 12 months.

Literatür Arşivi